References:

• Addressing the challenges of pancreatic cancer: future directions for improving outcomes.Pancreatology

  Hidalgo M, Cascinu S, Kleeff J, Labianca R, Löhr JM, Neoptolemos J, Real FX, Van Laethem JL, Heinemann V.
  Epub 2015 Jan-Feb;15(1):8-18. doi: 10.1016/j.pan.2014.10.001. 2014 Oct 17. Review.

• Pancreatic Cancer: Molecular Characterization, Clonal Evolution and Cancer Stem Cells.

  E, Castelli G, Testa U.Biomedicines
  Pelosi 2017 Nov 18;5(4). pii: E65. doi: 10.3390/biomedicines5040065. Review.

• Molecular Biomarkers of Pancreatic Intraepithelial Neoplasia and Their Implications in Early Diagnosis and Therapeutic Intervention of Pancreatic Cancer.

  Guo J, Xie K, Zheng S
  Int J Biol Sci. 2016 Jan 28;12(3):292-301. doi: 10.7150/ijbs.14995. eCollection 2016. Review.

• HER2/Neu (ErbB2) signaling to Rac1-Pak1 is temporally and spatially modulated by transforming growthfactor beta.

  Wang SE, Shin I, Wu FY, Friedman DB, Arteaga CL.
  Cancer Res. 2006 Oct 1;66(19):9591-600.

• Epidermal growth factor signaling in transformed cells.

  Lindsey S, Langhans SA.
  Int Rev Cell Mol Biol. 2015;314:1-41. doi: 10.1016/bs.ircmb.2014.10.001. Epub 2014 Nov 18. Review.

• The NF-κB Pathway and Cancer Stem Cells.

  Rinkenbaugh AL, Baldwin AS.
  Cells. 2016 Apr 6;5(2). pii: E16. doi: 10.3390/cells5020016. Review.

• The Janus Kinase (JAK) FERM and SH2 Domains: Bringing Specificity to JAK-Receptor Interactions.

  Ferrao R, Lupardus PJ
  Front Endocrinol (Lausanne). 2017 Apr 18;8:71. doi: 10.3389/fendo.2017.00071. eCollection 2017. Review.

• Cancer of the Pancreas: Molecular Pathways and Current Advancement in Treatment.

  Polireddy K, Chen Q.
  J Cancer. 2016 Jul 7;7(11):1497-514. doi: 10.7150/jca.14922. eCollection 2016. Review.

• Targeting CDK4 and CDK6: From Discovery to Therapy.

  Sherr CJ, Beach D, Shapiro GI.
  Cancer Discov. 2016 Apr;6(4):353-67. doi: 10.1158/2159-8290.CD-15-0894. Epub 2015 Dec 11. Review.

• CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer.

  Franco J, Witkiewicz AK, Knudsen ES
  Oncotarget. 2014 Aug 15;5(15):6512-25.

• p53-independent effects of Mdm2.

  Bohlman S, Manfredi JJ.
  Subcell Biochem. 2014;85:235-46. doi: 10.1007/978-94-017-9211-0_13. Review.

• Homologous recombination DNA repair genes play a critical role in reprogramming to a pluripotent state.

  González F, Georgieva D, Vanoli F, Shi ZD, Stadtfeld M, Ludwig T, Jasin M, Huangfu D.
  Cell Rep. 2013 Mar 28;3(3):651-60. doi: 10.1016/j.celrep.2013.02.005. Epub 2013 Mar 7.

• Genetic predisposition to pancreatic cancer.

  Ghiorzo P.
  World J Gastroenterol. 2014 Aug 21;20(31):10778-89. doi: 10.3748/wjg.v20.i31.10778. Review.

• Emerging targets in pancreatic cancer: epithelial-mesenchymal transition and cancer stem cells.

  Castellanos JA, Merchant NB, Nagathihalli NS.
  Onco Targets Ther. 2013 Sep 13;6:1261-7. doi: 10.2147/OTT.S34670. Review.

• Molecular targets for the treatment of pancreatic cancer: Clinical and experimental studies.

  Matsuoka T, Yashiro M.
  World J Gastroenterol. 2016 Jan 14;22(2):776-89. doi: 10.3748/wjg.v22.i2.776. Review.

• Targeting CDK4/6 in patients with cancer.

  Hamilton E, Infante JR.
  Cancer Treat Rev. 2016 Apr;45:129-38. doi: 10.1016/j.ctrv.2016.03.002. Epub 2016 Mar 8. Review.